Ho

Researchers are studying the ADHINCRA Program, which aims to improve the control of high blood pressure in Africa by addressing factors related to patients, healthcare providers, and health systems. This program hopes to reduce the risk of serious health problems like heart disease, stroke, and kidney disease by helping people manage their hypertension better. The study focuses on adults aged 18 to 70 years who have high blood pressure but do not have diabetes. The ADHINCRA Program is a nurse-led approach that includes home blood pressure monitoring, a mobile health app for support, lifestyle counseling, and a simplified treatment plan for hypertension. Participants either have not been treated for hypertension before or are on a single medication. The program is delivered through primary care centers at participating sites. Participants will be monitored for changes in their blood pressure over 12 months, with the main measure being the number of people whose systolic blood pressure falls below 140 mmHg. The study includes regular assessments and uses technology to support treatment adherence. The total participation period involves baseline measurements and follow-up at 12 months after starting the program.

Researchers are conducting a large multi-country project to estimate the prevalence of high-risk human papillomavirus (HPV) infections among girls and women aged 9 to 50 years in South Asia and sub-Saharan Africa. The study also aims to understand the incidence of persistent HPV infection over two years among sexually active young women. Alongside these surveys, qualitative studies will explore how gender norms and stigma affect HPV risk and access to prevention and treatment services. The study uses two main approaches: cross-sectional surveys (CSS) and longitudinal studies (LS). The CSS will enroll girls and women aged 9-50 from urban and rural areas, collecting urine samples for HPV testing and gathering data on demographics, sexual history, and HPV awareness. The LS will follow sexually active girls and women aged 15-35 for up to 24 months, testing for persistent HPV infection every six months using self-collected vaginal swabs and urine samples. In some countries, blood samples may also be collected. Qualitative sub-studies involving interviews and focus groups will be conducted in selected countries to better understand risk factors and barriers. Participants will provide samples and complete questionnaires on demographics, sexual and reproductive history, HPV vaccination, and screening. The study will measure HPV prevalence at a single time point and the incidence of infections lasting six months or longer. Safety and ethical considerations include informed consent for adults or assent with guardian consent for minors. The study is planned to run from late 2023 through 2026, with ongoing data collection and analysis across multiple countries and populations.